Targeting the BDNF/TrkB pathway for the treatment of tumors (Review)

Meng,Lingbin; Liu,Baoqiong; Ji,Rui; Jiang,Xin; Yan,Xuebo; Xin,Ying

doi:10.3892/ol.2018.9854

Targeting the BDNF/TrkB pathway for the treatment of tumors (Review)

Authors:
- Lingbin Meng
- Baoqiong Liu
- Rui Ji
- Xin Jiang
- Xuebo Yan
- Ying Xin
View Affiliations

Affiliations: Department of Internal Medicine, Florida Hospital, Orlando, FL 32803, USA, Department of Biology, Valencia College, Orlando, FL 32825, USA, Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Respiratory Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China, Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: December 20, 2018 https://doi.org/10.3892/ol.2018.9854
Pages: 2031-2039

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neurotrophins are a family of growth factors that regulate neural survival, development, function and plasticity in the central and the peripheral nervous system. There are four neurotrophins: nerve growth factor (NGF), brain‑derived neurotrophic factor (BDNF), neurotrophin‑3 (NT‑3) and NT‑4. Among them, BDNF is the most studied due to its high expression in the brain. Over the past two decades, BDNF and its receptor tropomyosin receptor kinase B (TrkB) have been reported to be upregulated in a wide range of tumors. This activated signal stimulates a series of downstream pathways, including phosphoinositide 3‑kinase/protein kinase B, Ras‑Raf‑mitogen activated protein kinase kinase‑extracellular signal‑regulated kinases, the phospholipase‑C‑γ pathway and the transactivation of epidermal growth factor receptor. Activation of these signaling pathways induces oncogenic effects by increasing cancer cell growth, proliferation, survival, migration and epithelial to mesenchymal transition, and decreasing anoikis, relapse and chemotherapeutic sensitivity. The present review summarizes recent findings to discuss the role of BDNF in tumors, the underlying molecular mechanism, targeting Trk receptors for treatment of cancers and its potential risk.

View Figures

View References

1	Bibel M and Barde YA: Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 14:2919–2937. 2000. View Article : Google Scholar : PubMed/NCBI
2	Huang EJ and Reichardt LF: Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci. 24:677–736. 2001. View Article : Google Scholar : PubMed/NCBI
3	Meldolesi J: Neurotrophin receptors in the pathogenesis, diagnosis and therapy of neurodegenerative diseases. Pharmacol Res. 121:129–137. 2017. View Article : Google Scholar : PubMed/NCBI
4	Reichardt LF: Neurotrophin-regulated signalling pathways. Rev Physiol Biochem Pharmacol. 361:1545–1564. 2006.
5	Meldolesi J: Neurotrophin Trk receptors: New targets for cancer therapy. Rev Physiol Biochem Pharmacol. 174:67–79. 2018. View Article : Google Scholar : PubMed/NCBI
6	Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X and Hondermarck H: Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res. 17:1741–1752. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ricci A, Graziano P, Mariotta S, Cardillo G, Sposato B, Terzano C and Bronzetti E: Neurotrophin system expression in human pulmonary carcinoid tumors. Growth Factors. 23:303–312. 2005. View Article : Google Scholar : PubMed/NCBI
8	Moon A, Won KY, Lee JY, Kang I, Lee SK and Lee J: Expression of BDNF, TrkB, and p53 in early-stage squamous cell carcinoma of the uterine cervix. Pathology. 43:453–458. 2011. View Article : Google Scholar : PubMed/NCBI
9	Brunetto de Farias C, Rosemberg DB, Heinen TE, Koehler-Santos P, Abujamra AL, Kapczinski F, Brunetto AL, Ashton-Prolla P, Meurer L, Reis Bogo M, et al: BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer. Oncology. 79:430–439. 2010. View Article : Google Scholar : PubMed/NCBI
10	Gilbertson RJ and Rich JN: Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 7:733–736. 2007. View Article : Google Scholar : PubMed/NCBI
11	Tanaka K, Okugawa Y, Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Araki T, Uchida K, Mohri Y and Kusunoki M: Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. PLoS One. 9:e964102014. View Article : Google Scholar : PubMed/NCBI
12	Okamura K, Harada T, Wang S, Ijichi K, Furuyama K, Koga T, Okamoto T, Takayama K, Yano T and Nakanishi Y: Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer. 78:100–106. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lange AM and Lo HW: Inhibiting TRK proteins in clinical cancer therapy. Cancers (Basel). 10(pii): E1052018. View Article : Google Scholar : PubMed/NCBI
14	Tanaka J, Horiike Y, Matsuzaki M, Miyazaki T, Ellis-Davies GC and Kasai H: Protein synthesis and neurotrophin-dependent structural plasticity of single dendritic spines. Science. 319:1683–1687. 2008. View Article : Google Scholar : PubMed/NCBI
15	Horch HW and Katz LC: BDNF release from single cells elicits local dendritic growth in nearby neurons. Nat Neurosci. 5:1177–1184. 2002. View Article : Google Scholar : PubMed/NCBI
16	Figurov A, Pozzo-Miller LD, Olafsson P, Wang T and Lu B: Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature. 381:706–709. 1996. View Article : Google Scholar : PubMed/NCBI
17	Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, Tecott LH and Reichardt LF: Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 6:736–742. 2003. View Article : Google Scholar : PubMed/NCBI
18	Cao L, Lin EJ, Cahill MC, Wang C, Liu X and During MJ: Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat Med. 15:447–454. 2009. View Article : Google Scholar : PubMed/NCBI
19	Meng L, Huang T, Sun C, Hill DL and Krimm R: BDNF is required for taste axon regeneration following unilateral chorda tympani nerve section. Exp Neurol. 293:27–42. 2017. View Article : Google Scholar : PubMed/NCBI
20	Meng L, Ohman-Gault L, Ma L and Krimm RF: Taste bud-derived BDNF is required to maintain normal amounts of innervation to adult taste buds. eNeuro. 2(pii): ENEURO.0097-15.2015. 2015.PubMed/NCBI
21	Meng L, Jiang X and Ji R: Role of neurotrophin in the taste system following gustatory nerve injury. Metab Brain Dis. 30:605–613. 2015. View Article : Google Scholar : PubMed/NCBI
22	Ji R, Meng L, Li Q and Lu Q: TAM receptor deficiency affects adult hippocampal neurogenesis. Metab Brain Dis. 30:633–644. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ji R, Meng L, Jiang X, Cvm NK, Ding J, Li Q and Lu Q: TAM receptors support neural stem cell survival, proliferation and neuronal differentiation. PLoS One. 9:e1151402014. View Article : Google Scholar : PubMed/NCBI
24	Li Q, Ford MC, Lavik EB and Madri JA: Modeling the neurovascular niche: VEGF- and BDNF-mediated cross-talk between neural stem cells and endothelial cells: An in vitro study. J Neurosci Res. 84:1656–1668. 2006. View Article : Google Scholar : PubMed/NCBI
25	Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Müller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN and LaFerla FM: Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA. 106:13594–13599. 2009. View Article : Google Scholar : PubMed/NCBI
26	Pearse RN, Swendeman SL, Li Y, Rafii D and Hempstead BL: A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 105:4429–4436. 2005. View Article : Google Scholar : PubMed/NCBI
27	Nakagawara A: Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett. 169:107–114. 2001. View Article : Google Scholar : PubMed/NCBI
28	Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V and Evans AE: Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 15:3244–3250. 2009. View Article : Google Scholar : PubMed/NCBI
29	Porter AC and Vaillancourt RR: Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene. 17:(11 Reviews). 1343–1352. 1998. View Article : Google Scholar : PubMed/NCBI
30	Nakagawara A, Azar CG, Scavarda NJ and Brodeur GM: Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol. 14:759–767. 1994. View Article : Google Scholar : PubMed/NCBI
31	Yin B, Ma ZY, Zhou ZW, Gao WC, Du ZG, Zhao ZH and Li QQ: The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. Oncogene. 34:761–770. 2015. View Article : Google Scholar : PubMed/NCBI
32	Zhang SY, Hui LP, Li CY, Gao J, Cui ZS and Qiu XS: More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells. BMC Cancer. 16:1712016. View Article : Google Scholar : PubMed/NCBI
33	Radin DP and Patel P: BDNF: An oncogene or tumor suppressor? Anticancer Res. 37:3983–3990. 2017.PubMed/NCBI
34	Hwang JJ, Park MH, Choi SY and Koh JY: Activation of the Trk signaling pathway by extracellular zinc. Role of metalloproteinases. J Biol Chem. 280:11995–12001. 2005. View Article : Google Scholar : PubMed/NCBI
35	Hempstead BL: Dissecting the diverse actions of pro-and mature neurotrophins. Curr Alzheimer Res. 3:19–24. 2006. View Article : Google Scholar : PubMed/NCBI
36	Johnston AL, Lun X, Rahn JJ, Liacini A, Wang L, Hamilton MG, Parney IF, Hempstead BL, Robbins SM, Forsyth PA, et al: The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Biol. 5:e2122007. View Article : Google Scholar : PubMed/NCBI
37	Herrmann JL, Menter DG, Hamada J, Marchetti D, Nakajima M and Nicolson GL: Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol Biol Cell. 4:1205–1216. 1993. View Article : Google Scholar : PubMed/NCBI
38	Marchetti D, Aucoin R, Blust J, Murry B and Greiter-Wilke A: p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. J Cell Biochem. 91:206–215. 2004. View Article : Google Scholar : PubMed/NCBI
39	Khwaja F and Djakiew D: Inhibition of cell-cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor. Mol Carcinog. 36:153–160. 2003. View Article : Google Scholar : PubMed/NCBI
40	Yuanlong H, Haifeng J, Xiaoyin Z, Jialin S, Jie L, Li Y, Huahong X, Jiugang S, Yanglin P, Kaichun W, et al: The inhibitory effect of p75 neurotrophin receptor on growth of human hepatocellular carcinoma cells. Cancer Lett. 268:110–119. 2008. View Article : Google Scholar : PubMed/NCBI
41	Jin H, Pan Y, He L, Zhai H, Li X, Zhao L, Sun L, Liu J, Hong L, Song J, et al: p75 neurotrophin receptor inhibits invasion and metastasis of gastric cancer. Mol Cancer Res. 5:423–433. 2007. View Article : Google Scholar : PubMed/NCBI
42	Ji R, Tian S, Lu HJ and Lu Q, Zheng Y, Wang X, Ding J, Li Q and Lu Q: TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell activation. J Immunol. 191:6165–6177. 2013. View Article : Google Scholar : PubMed/NCBI
43	Puehringer D, Orel N, Lüningschrör P, Subramanian N, Herrmann T, Chao MV and Sendtner M: EGF transactivation of Trk receptors regulates the migration of newborn cortical neurons. Nat Neurosci. 16:407–415. 2013. View Article : Google Scholar : PubMed/NCBI
44	Park JR, Eggert A and Caron H: Neuroblastoma: Biology, prognosis, and treatment. Hematol Oncol Clin North Am. 24:65–86. 2010. View Article : Google Scholar : PubMed/NCBI
45	Kermani P and Hempstead B: Brain-derived neurotrophic factor: A newly described mediator of angiogenesis. Trends Cardiovasc Med. 17:140–143. 2007. View Article : Google Scholar : PubMed/NCBI
46	Kermani P, Rafii D, Jin DK, Whitlock P, Schaffer W, Chiang A, Vincent L, Friedrich M, Shido K, Hackett NR, et al: Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest. 115:653–663. 2005. View Article : Google Scholar : PubMed/NCBI
47	Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE and Brodeur GM: Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 62:6462–6466. 2002.PubMed/NCBI
48	Brierley GV, Priebe IK, Purins L, Fung KY, Tabor B, Lockett T, Nice E, Gibbs P, Tie J, McMurrick P, et al: Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients. Cancer Biomark. 13:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
49	Xiong L, Deng X, Wen Y, Yang Z and Miao X: Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions. World J Surg Oncol. 11:802013. View Article : Google Scholar : PubMed/NCBI
50	Choi B, Lee EJ, Shin MK, Park YS, Ryu MH, Kim SM, Kim EY, Lee HK and Chang EJ: Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3. Oncotarget. 7:55506–55517. 2016. View Article : Google Scholar : PubMed/NCBI
51	Götz R and Sendtner M: Cooperation of tyrosine kinase receptor TrkB and epidermal growth factor receptor signaling enhances migration and dispersal of lung tumor cells. PLoS One. 9:e1009442014. View Article : Google Scholar : PubMed/NCBI
52	Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Kouttab N, Chu W and Wan Y: Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. Int J Oncol. 29:1003–1011. 2006.PubMed/NCBI
53	de Farias CB, Heinen TE, dos Santos RP, Abujamra AL, Schwartsmann G and Roesler R: BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. Biochem Biophys Res Commun. 425:328–332. 2012. View Article : Google Scholar : PubMed/NCBI
54	Heinen TE, dos Santos RP, da Rocha A, Dos Santos MP, Lopez PL, Silva Filho MA, Souza BK, Rivero LF, Becker RG, Gregianin LJ, et al: Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma. Oncotarget. 7:348602016. View Article : Google Scholar : PubMed/NCBI
55	Yee CL, Jones KR and Finger TE: Brain-derived neurotrophic factor is present in adult mouse taste cells with synapses. J Comp Neurol. 459:15–24. 2003. View Article : Google Scholar : PubMed/NCBI
56	Makino K, Kawamura K, Sato W, Kawamura N, Fujimoto T and Terada Y: Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling. PLoS One. 7:e410492012. View Article : Google Scholar : PubMed/NCBI
57	Iyer R, Evans AE, Qi X, Ho R, Minturn JE, Zhao H, Balamuth N, Maris JM and Brodeur GM: Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res. 16:1478–1485. 2010. View Article : Google Scholar : PubMed/NCBI
58	Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, et al: Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 372:179–186. 2016. View Article : Google Scholar : PubMed/NCBI
59	Jaboin J, Kim CJ, Kaplan DR and Thiele CJ: Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res. 62:6756–6763. 2002.PubMed/NCBI
60	Bao W, Qiu H, Yang T, Luo X, Zhang H and Wan X: Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One. 8:e706162013. View Article : Google Scholar : PubMed/NCBI
61	Kupferman M, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D and Myers JN: TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 29:2047–2059. 2010. View Article : Google Scholar : PubMed/NCBI
62	Ricci A, De Vitis C, Noto A, Fattore L, Mariotta S, Cherubini E, Roscilli G, Liguori G, Scognamiglio G, Rocco G, et al: TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung. Cell Cycle. 12:1696–1703. 2013. View Article : Google Scholar : PubMed/NCBI
63	Smit MA, Geiger TR, Song JY, Gitelman I and Peeper DS: A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol. 29:3722–3737. 2009. View Article : Google Scholar : PubMed/NCBI
64	Lee J, Jiffar T and Kupferman ME: A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma. PLoS One. 7:e302462012. View Article : Google Scholar : PubMed/NCBI
65	Xia H, Li Y and Lv X: MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer. Int J Oncol. 49:1325–1333. 2016. View Article : Google Scholar : PubMed/NCBI
66	DeWitt J, Ochoa V, Urschitz J, Elston M, Moisyadi S and Nishi R: Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line. Oncogene. 33:977–985. 2014. View Article : Google Scholar : PubMed/NCBI
67	Chen B, Liang Y, He Z, An Y, Zhao W and Wu J: Autocrine activity of BDNF induced by the STAT3 signaling pathway causes prolonged TrkB activation and promotes human non-small-cell lung cancer proliferation. Sci Rep. 6:304042016. View Article : Google Scholar : PubMed/NCBI
68	Navé BT, Ouwens M, Withers DJ, Alessi DR and Shepherd PR: Mammalian target of rapamycin is a direct target for protein kinase B: Identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 344:427–431. 1999. View Article : Google Scholar : PubMed/NCBI
69	Aoki M, Blazek E and Vogt PK: A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA. 98:136–141. 2001. View Article : Google Scholar : PubMed/NCBI
70	Martens LK, Kirschner KM, Warnecke C and Scholz H: Hypoxia-inducible factor-1 (HIF-1) is a transcriptional activator of the TrkB neurotrophin receptor gene. J Biol Chem. 282:14379–14388. 2007. View Article : Google Scholar : PubMed/NCBI
71	Li Z, Zhang J, Liu Z, Woo CW and Thiele CJ: Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ. 14:318–326. 2007. View Article : Google Scholar : PubMed/NCBI
72	Radin D, Lippa A, Patel P and Leonardi D: Lifeguard inhibition of Fas-mediated apoptosis: A possible mechanism for explaining the cisplatin resistance of triple-negative breast cancer cells. Biomed Pharmacother. 77:161–166. 2016. View Article : Google Scholar : PubMed/NCBI
73	Voldborg BR, Damstrup L, Spang-Thomsen M and Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 8:1197–1206. 1997. View Article : Google Scholar : PubMed/NCBI
74	Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582. 1994. View Article : Google Scholar : PubMed/NCBI
75	Bos JL: Ras oncogenes in human cancer: A review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
76	Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem. 268:14553–14556. 1993.PubMed/NCBI
77	Sinkevicius KW, Kriegel C, Bellaria KJ, Lee J, Lau AN, Leeman KT, Zhou P, Beede AM, Fillmore CM, Caswell D, et al: Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Natl Acad Sci USA. 111:10299–10304. 2014. View Article : Google Scholar : PubMed/NCBI
78	Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, et al: Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: Possibilities for therapeutic intervention. Oncotarget. 5:4603–4650. 2014. View Article : Google Scholar : PubMed/NCBI
79	Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, et al: Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci USA. 108:19024–19029. 2011. View Article : Google Scholar : PubMed/NCBI
80	Lee DH, Szczepanski MJ and Lee YJ: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem. 106:1113–1122. 2009. View Article : Google Scholar : PubMed/NCBI
81	Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 77:841–852. 1994. View Article : Google Scholar : PubMed/NCBI
82	Huang EJ and Reichardt LF: Trk receptors: Roles in neuronal signal transduction. Annu Rev Biochem. 72:609–642. 2003. View Article : Google Scholar : PubMed/NCBI
83	Siu MK, Wong OG and Cheung AN: TrkB as a therapeutic target for ovarian cancer. Expert Opin Ther Targets. 13:1169–1178. 2009. View Article : Google Scholar : PubMed/NCBI
84	Yuan Y, Ye HQ and Ren QC: Upregulation of the BDNF/TrKB pathway promotes epithelial-mesenchymal transition, as well as the migration and invasion of cervical cancer. Int J Oncol. 52:461–472. 2018.PubMed/NCBI
85	Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A and Prémont J: Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS One. 5:e97772010. View Article : Google Scholar : PubMed/NCBI
86	Cazorla M, Prémont J, Mann A, Girard N, Kellendonk C and Rognan D: Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest. 121:1846–1857. 2011. View Article : Google Scholar : PubMed/NCBI
87	Light JE, Koyama H, Minturn JE, Ho R, Simpson AM, Iyer R, Mangino JL, Kolla V, London WB and Brodeur GM: Clinical significance of NTRK family gene expression in neuroblastomas. Pediatr Blood Cancer. 59:226–232. 2012. View Article : Google Scholar : PubMed/NCBI
88	Bertrand T, Kothe M, Liu J, Dupuy A, Rak A, Berne PF, Davis S, Gladysheva T, Valtre C, Crenne JY and Mathieu M: The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol. 423:439–453. 2012. View Article : Google Scholar : PubMed/NCBI
89	Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, et al: Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7:400–409. 2017. View Article : Google Scholar : PubMed/NCBI
90	Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, et al: Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther. 15:628–639. 2016. View Article : Google Scholar : PubMed/NCBI
91	Burris HA, Shaw AT, Bauer TM, Farago AF, Doebele RC, Smith S, Nanda N, Cruickshank S, Low JA and Brose MS: Pharmacokinetics (PK) of LOXO-101 during the first-in-human phase I study in patients with advanced solid tumors: Interim update. Cancer Res. 75:45292015. View Article : Google Scholar
92	Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 378:731–739. 2018. View Article : Google Scholar : PubMed/NCBI
93	Al-Salama ZT and Keating GM: Cabozantinib: A review in advanced renal cell carcinoma. Drugs. 76:1771–1778. 2016. View Article : Google Scholar : PubMed/NCBI
94	Abdelaziz A and Vaishampayan U: Cabozantinib for renal cell carcinoma: Current and future paradigms. Curr Treat Options Oncol. 18:182017. View Article : Google Scholar : PubMed/NCBI
95	Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA and Wen PY: Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 122:582–587. 2016. View Article : Google Scholar : PubMed/NCBI
96	Radin DP, Zhong S, Purcell R and Lippa A: Acute ampakine treatment ameliorates age-related deficits in long-term potentiation. Biomed Pharmacother. 84:806–809. 2016. View Article : Google Scholar : PubMed/NCBI
97	Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, et al: Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 10:(1 Suppl 1). S1–S63. 2015. View Article : Google Scholar : PubMed/NCBI
98	Cao L, Liu X, Lin EJ, Wang C, Choi EY, Riban V, Lin B and During MJ: Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell. 142:52–64. 2010. View Article : Google Scholar : PubMed/NCBI
99	Liu X, McMurphy T, Xiao R, Slater A, Huang W and Cao L: Hypothalamic gene transfer of BDNF inhibits breast cancer progression and metastasis in middle age obese mice. Mol Ther. 22:1275–1284. 2014. View Article : Google Scholar : PubMed/NCBI
100	Xiao R, Bergin SM, Huang W, Slater AM, Liu X, Judd RT, Lin ED, Widstrom KJ, Scoville SD, Yu J, et al: Environmental and genetic activation of hypothalamic BDNF modulates T-cell immunity to exert an anticancer phenotype. Cancer Immunol Res. 4:488–497. 2016. View Article : Google Scholar : PubMed/NCBI
101	Garofalo S, D'Alessandro G, Chece G, Brau F, Maggi L, Rosa A, Porzia A, Mainiero F, Esposito V, Lauro C, et al: Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice. Nat Commun. 6:66232015. View Article : Google Scholar : PubMed/NCBI
102	Linker RA, Lee DH, Flach AC, Litke T, van den Brandt J, Reichardt HM, Lingner T, Bommhardt U, Sendtner M, Gold R, et al: Thymocyte-derived BDNF influences T-cell maturation at the DN3/DN4 transition stage. Eur J Immunol. 45:1326–1338. 2015. View Article : Google Scholar : PubMed/NCBI
103	Jaboin J, Hong A, Kim CJ and Thiele CJ: Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Lett. 193:109–114. 2003. View Article : Google Scholar : PubMed/NCBI
104	Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M and Toyka KV: A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 1:201–206. 2000. View Article : Google Scholar : PubMed/NCBI
105	Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C and Rask CA: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology. 51:695–702. 1998. View Article : Google Scholar : PubMed/NCBI
106	Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, Penn R, Goetz CG and Comella CD: Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 46:419–424. 1999. View Article : Google Scholar : PubMed/NCBI
107	Radin DP, Purcell R and Lippa AS: Oncolytic properties of ampakines in vitro. Anticancer Res. 38:265–269. 2018.PubMed/NCBI